The Pharma Data

JANUARY 26, 2021

Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies. During this time, he grew the medical, clinical, and regulatory groups, and established an in-house pharmacovigilance function.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

JANUARY 27, 2021

.–( BUSINESS WIRE )– PlateletBio , a pioneering biotechnology company developing next-generation allogeneic cell therapies for treatment of human diseases, has named Steven M. A recognized gene and cell therapy expert, Dr. Altschuler co-founded Spark Therapeutics, taking it from launch to its $4B acquisition by Roche.

Therapies 40

Therapies Clinical Development Engineering Disease 40

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

The Pharma Data

DECEMBER 21, 2020

The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.

Vaccine 52

Vaccine Trials Clinical Trials Clinical Development 52

The Pharma Data

DECEMBER 9, 2020

The FURI study is evaluating oral ibrexafungerp as a salvage treatment in patients with a variety of difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to, intolerant of current standards of care, or require a non-azole oral step-down therapy for treatment of azole-resistant species. JERSEY CITY, N.J.,

Hospitals 52

Hospitals Pharmacokinetics Treatment Trials 52

Drug Target Review

JULY 1, 2024

Overall, SRP-001’s modulation of pain signalling genes and pathways through endocannabinoid enhancement and FAAH inhibition supports its potential as an effective non-opioid pain therapeutic, validating the planned clinical trials. was founded in 2016 to develop safer, non-opioid therapies for acute and chronic pain.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , AR-301 (VAP). AR-101 (HAP).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 18, 2020

Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

OCTOBER 25, 2020

Agitation associated with delirium is commonly seen in numerous hospital settings, resulting in serious medical complications and extended hospital stays. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. NEW HAVEN, Conn.,

Treatment 40

Treatment Trials FDA Hospitals 40

The Pharma Data

MAY 27, 2022

of patients refractory to their initial therapy and about one-third (33.1%) having received prior CAR T-cell therapy.¹ The pivotal phase II NP30179 expansion study included patients with heavily pre-treated and highly refractory DLBCL, with 58.3% After a median follow-up of 12.6 months, 39.4%

Treatment 52

Treatment Therapies Clinical Trials Disease 52

The Pharma Data

DECEMBER 14, 2020

Specifically, it is being examined in adults who are hospitalized with COVID-19. “With the clinical program at AbbVie now underway, we are in a position to contribute a new therapeutic option to address this pandemic.” ” Under the license agreement, the development of ABBV-47D11 will be greatly advanced.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

JUNE 7, 2023

Rahway, NJ, USA), an anti-PD-1 therapy. The updated results from TROPION-Lung02 signal the potential for datopotamab deruxtecan combinations to improve outcomes for patients with non-small cell lung cancer and are a promising development in the pursuit of a new standard treatment option beyond immunotherapy.”

Trials 40

Trials Protein Expression Therapies Treatment 40

Precision for Medicine

JUNE 26, 2023

Unraveling the complexity of manufacturing next-gen biologics is critical to the shared mission of accelerating patient access to new therapies,” said Chad Clark, President of Precision for Medicine. This convergence is driving faster clinical development and approval. For more information, visit PrecisionForMedicine.com.

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

MARCH 23, 2021

Chief, Department of Head and Neck Medical Oncology, National Cancer Center Hospital East. We have the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. About Oncology at Bayer.

Treatment 52

Treatment Clinical Trials Trials Clinical Development 52

The Pharma Data

OCTOBER 19, 2020

. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D.,

Clinical Trials 52

Clinical Trials RNA DNA Science 52

Drug Target Review

AUGUST 16, 2024

Advances in gene editing, personalised medicine, and regenerative therapies are improving patient outcomes and changing the landscape of healthcare. She has also served as a leader in clinical development and medical affairs at AbbVie, Kimberly-Clark and Johnson & Johnson.

Medical Schools 111

Medical Schools Nurses Research Production 111

The Pharma Data

JANUARY 21, 2021

Prior to joining Labcorp, she held multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. She succeeds Dot Adcock, who retired. She also served as the CMO of Akashi Therapeutics, Inc. ,

Laboratories 52

Laboratories Pharmaceuticals Clinical Development Engineering 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1?,

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 12, 2021

The FDA Fast Track program is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The FDA Fast Track program is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

FDA 40

FDA Treatment Trials Clinical Trials 40

The Pharma Data

JUNE 1, 2022

With more than two decades of biopharmaceutical R&D experience, Dr. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

JANUARY 14, 2021

Clinical Development – Pipeline Review. He is also a Chief Investigator for five international randomized controlled clinical trials in IgA nephropathy, and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. . 3:40pm.

Clinical Trials 40

Clinical Trials Disease Hospitals International 40

Altus Drug Development

MAY 31, 2022

The focus of R&D efforts during the creation of value-based treatments changes depending on the type of medicinal products being developed. A clinical development program may be needed in case certain changes to a drug have been made. Doctors have the freedom to choose between more treatment options.

Treatment 52

Treatment Pharmaceuticals Production Doctors 52

The Pharma Data

AUGUST 29, 2020

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab. Régis Peffault de Latour, Head of the French Reference Center for Aplastic Anemia and PNH, Saint-Louis Hospital, and University of Paris, are principal investigators of the study.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

OCTOBER 19, 2020

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2020

This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

JULY 8, 2021

Patients should call their healthcare provider or go to the nearest hospital emergency room right away if they have any of the symptoms listed above. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). Clinical results in the overall population (n=799): On the key clinical endpoint, treatment with REGN-COV2 reduced COVID-19 related medical visits by 57% through day 29 (2.8%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

NOVEMBER 9, 2020

We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. Albert Bourla, Pfizer Chairman and CEO. “We About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 1, 2020

will reduce the number of people in the high-risk population being hospitalized. The data submitted to regulatory agencies around the world are the result of a scientifically rigorous and highly ethical research and development program.”. “The Emergency Use Authorization in the U.K. CEO and Co-founder of BioNTech. “We

Vaccine 40

Vaccine Clinical Trials Trials Production 40

Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 116

Therapies Disease Engineering Medical Schools 116

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. This patient population is at significant risk of developing cardiovascular complications, which are frequently fatal, during their illness.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

SEPTEMBER 11, 2021

– Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction. vice president, Product Development, Lilly.

Therapies 52

Therapies FDA Hospitals FDA Approval 52

Drug Target Review

OCTOBER 16, 2024

It’s an exciting process—anticipating development risks, predicting outcomes, and aligning these with the greater vision of medical advancement. The true joy comes from navigating these complexities and asking the right questions early on, because these foundational steps are critical to the success of any clinical development process.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52